INVO Bioscience Appoints Meryle Lynn Chamberlain to Lead Marketing for Global Brand Expansion
Aggressive go-to-market sales, partnerships, and marketing strategy to bring INVOcell, fertility care that is accessible, inclusive, and affordable to the more than 90% of couples in need of fertility treatment that currently go without care.
News provided by
Share this article
SARASOTA, Fla., May 10, 2021 /PRNewswire/
INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women s health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company.